Korean J Ophthalmol.  2014 Jun;28(3):197-206. 10.3341/kjo.2014.28.3.197.

Korean Guidelines for the Diagnosis and Management of Dry Eye: Development and Validation of Clinical Efficacy

• Hyon JY
• Kim HM
• Lee D
• Chung ES
• Song JS
• Choi CY
• Lee J
• Korean Corneal Disease Study Group

• KMID: 2133317
• DOI: http://doi.org/10.3341/kjo.2014.28.3.197

Abstract

PURPOSE
To evaluate the clinical efficacy of newly developed guidelines for the diagnosis and management of dry eye.
METHODS
This retrospective, multi-center, non-randomized, observational study included a total of 1,612 patients with dry eye disease who initially visited the clinics from March 2010 to August 2010. Korean guidelines for the diagnosis and management of dry eye were newly developed from concise, expert-consensus recommendations. Severity levels at initial and final visits were determined using the guidelines in patients with 90 +/- 7 days of follow-up visits (n = 526). Groups with different clinical outcomes were compared with respect to clinical parameters, treatment modalities, and guideline compliance. Main outcome measures were ocular and visual symptoms, ocular surface disease index, global assessment by patient and physician, tear film break-up time, Schirmer-1 test score, ocular surface staining score at initial and final visits, clinical outcome after three months of treatment, and guideline compliance.
RESULTS
Severity level was reduced in 47.37% of patients treated as recommended by the guidelines. Younger age (odd ratio [OR], 0.984; p = 0.044), higher severity level at initial visit, compliance to treatment recommendation (OR, 1.832; p = 0.047), and use of topical cyclosporine (OR, 1.838; p = 0.011) were significantly associated with improved clinical outcomes.
CONCLUSIONS
Korean guidelines for the diagnosis and management of dry eye can be used as a valid and effective tool for the treatment of dry eye disease.

Keyword

Dry eye syndrome; Practice guideline; Standards

MeSH Terms

Adult
Aged
Aged, 80 and over
Diagnostic Techniques, Ophthalmological/*standards
*Disease Management
Dry Eye Syndromes/*diagnosis/*drug therapy/epidemiology
Female
Follow-Up Studies
Humans
Immunosuppressive Agents/*administration & dosage
Male
Middle Aged
Morbidity/trends
Ophthalmic Solutions
*Practice Guidelines as Topic
Republic of Korea/epidemiology
Retrospective Studies
Young Adult
Immunosuppressive Agents
Ophthalmic Solutions

Figure

• 

  Fig. 1 Distribution of severity level of dry eye (DE) disease at the initial visit (n = 1,612) (Korean Corneal Disease Study Group guidelines).

• 

  Fig. 2 Severity level of dry eye disease at the initial and final visits (n = 526) (Korean Corneal Disease Study Group guidelines).

• 

  Fig. 3 Changes of subjective (A-D) and objective (E-H) clinical parameters in dry eye patients (n = 526) of each initial severity level (Korean Corneal Disease Study Group guidelines). (A) Ocular surface disease index (%), (B) irritation and visual symptoms (1, sometimes; 2, often; 3, always; 4, daily life limited), (C) visual symptom, (D) subjective global assessment (0 [best] to 5 [worst]), (E) tear film break up time (sec), (F) Schirmer-1 test score (mm/5 min), (G) ocular surface staining score (Oxford scale), (H) objective global assessment (0 [best] to 5 [worst]).

Reference

1. Lemp MA. Report of the National Eye Institute/Industry workshop on clinical trials in dry eyes. CLAO J. 1995; 21:221–232.

2. Behrens A, Doyle JJ, Stern L, et al. Dysfunctional tear syndrome: a Delphi approach to treatment recommendations. Cornea. 2006; 25:900–907.

3. The definition and classification of dry eye disease: report of the Definition and Classification Subcommittee of the International Dry Eye WorkShop (2007). Ocul Surf. 2007; 5:75–92.

4. Methodologies to diagnose and monitor dry eye disease: report of the Diagnostic Methodology Subcommittee of the International Dry Eye WorkShop (2007). Ocul Surf. 2007; 5:108–152.

5. Han SB, Hyon JY, Woo SJ, et al. Prevalence of dry eye disease in an elderly Korean population. Arch Ophthalmol. 2011; 129:633–638.

6. The epidemiology of dry eye disease: report of the Epidemiology Subcommittee of the International Dry Eye Work-Shop (2007). Ocul Surf. 2007; 5:93–107.

7. Nichols KK, Nichols JJ, Mitchell GL. The lack of association between signs and symptoms in patients with dry eye disease. Cornea. 2004; 23:762–770.

8. Nichols KK, Smith JA. Association of clinical diagnostic tests and dry eye surveys: the NEI-VFQ-25 and the OSDI. Adv Exp Med Biol. 2002; 506(Pt B):1177–1181.

9. Bron AJ, Evans VE, Smith JA. Grading of corneal and conjunctival staining in the context of other dry eye tests. Cornea. 2003; 22:640–650.

10. Schiffman RM, Christianson MD, Jacobsen G, et al. Reliability and validity of the Ocular Surface Disease Index. Arch Ophthalmol. 2000; 118:615–621.

11. Nelson JD, Shimazaki J, Benitez-del-Castillo JM, et al. The international workshop on meibomian gland dysfunction: report of the definition and classification subcommittee. Invest Ophthalmol Vis Sci. 2011; 52:1930–1937.

12. Wilson SE, Stulting RD. Agreement of physician treatment practices with the international task force guidelines for diagnosis and treatment of dry eye disease. Cornea. 2007; 26:284–289.

13. Perry HD, Solomon R, Donnenfeld ED, et al. Evaluation of topical cyclosporine for the treatment of dry eye disease. Arch Ophthalmol. 2008; 126:1046–1050.

14. Management and therapy of dry eye disease: report of the Management and Therapy Subcommittee of the International Dry Eye WorkShop (2007). Ocul Surf. 2007; 5:163–178.

15. Baiza-Duran L, Medrano-Palafox J, Hernandez-Quintela E, et al. A comparative clinical trial of the efficacy of two different aqueous solutions of cyclosporine for the treatment of moderate-to-severe dry eye syndrome. Br J Ophthalmol. 2010; 94:1312–1315.

16. Barber LD, Pflugfelder SC, Tauber J, Foulks GN. Phase III safety evaluation of cyclosporine 0.1% ophthalmic emulsion administered twice daily to dry eye disease patients for up to 3 years. Ophthalmology. 2005; 112:1790–1794.

17. Sall K, Stevenson OD, Mundorf TK, Reis BL. CsA Phase 3 Study Group. Two multicenter, randomized studies of the efficacy and safety of cyclosporine ophthalmic emulsion in moderate to severe dry eye disease. Ophthalmology. 2000; 107:631–639.